Message From Senior Management
601 21st Street, Suite 300 Vero Beach, FL 32960 February 11, 2025 Dear Shareholder: Our fiscal year will end March 31, 2025, and this year has proven to be challenging, yet productive. We [...]
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), a clinical-stage biotechnology [...]
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, [...]
Marble Arch Research: What is Pritumumab and How it Works
CLICK HERE TO DOWNLOAD COMPLETE PDF
Nascent Biotech Regains Worldwide Rights for Pritumumab
NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
NBIO Link Report for May 10, 2023
Wall Street PR Apple News StreetInsider.com QuoteMedia WallStreetPR Facebook LinkedIn
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
A Letter to Nascent Biotech Shareholders, May 1, 2023
Dear Shareholder, Your continued support of Nascent Biotech is very much appreciated by the Company’s management. Without it, we could not have achieved the completion of our Phase I Clinical [...]